Pharmaceutical formulation containing gelling agent
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
1. A controlled release oral solid dosage form comprising:
(i) a first population of coated particles comprising an opioid analgesic coated with a controlled release material, and
(ii) a second population of coated particles comprising polyethylene oxide coated with an acrylic polymer,
the dosage form providing a therapeutic effect for about 12 hours to about 24 hours when orally administered to a human patient, and when dissolved in from about 0.5 ml to about 10 ml of an aqueous liquid, forming a viscous gel,
wherein the coated particles of the second population are about 0.5 mm to about 2 mm in diameter and are free from the opioid analgesic.
2. The controlled release oral solid dosage form of claim 1 , wherein the viscous gel is unsuitable for injection.
3. The controlled release oral solid dosage form of claim 1 , wherein the coated particles of the second population consist of said polyethylene oxide, said acrylic polymer and one or more additional pharmaceutically acceptable excipient(s).
4. The controlled release oral solid dosage form of claim 3 , wherein the acrylic polymer is an ammonio methacrylate copolymer.
5. The controlled release oral solid dosage form of claim 1 , wherein the viscous gel cannot be injected through an insulin syringe.
6. The controlled release oral solid dosage form of claim 1 , wherein the coated particles of the second population comprise polyvinylpyrrolidone.
7. The controlled release oral solid dosage form of claim 4 , wherein the coated particles of the first population and the coated particles of the second population are contained in a pharmaceutically acceptable capsule.
8. The controlled release oral solid dosage form of claim 7 , wherein the coated particles of the first population are about 0.5 mm to about 2 mm in diameter.
9. The controlled release oral solid dosage form of claim 1 , wherein the viscous gel cannot be drawn into an insulin syringe.
10. The controlled release oral solid dosage form of claim 1 , wherein the coated particles of the first population and the coated particles of the second population have a diameter of about 0.5 mm.
11. The controlled release oral solid dosage form of claim 1 , wherein the viscous gel has a viscosity of at least about 10 cP.
12. The controlled release oral solid dosage form of claim 1 , wherein the viscous gel has a viscosity of at least about 60 cP.
13. The controlled release oral solid dosage form of claim 1 , wherein the viscous gel has a viscosity of from 120 cP to 5000 cP.
14. The controlled release oral solid dosage form of claim 1 , wherein the viscous gel has a viscosity of from 375 cP to 5000 cP.
15. The controlled release oral solid dosage form of claim 1 , wherein the viscous gel has a viscosity of from 2,000 cP to 5000 cP.
16. The controlled release oral solid dosage form of claim 1 , wherein the viscous gel has a viscosity of from 120 cP to 5,000 cP.
17. A controlled release oral solid dosage form comprising a capsule containing:
(i) a first population of coated particles comprising an opioid analgesic coated with a controlled release material, and
(ii) a second population of coated particles comprising polyethylene oxide coated with an acrylic polymer,
the dosage form providing a therapeutic effect for about 12 hours when orally administered to a human patient, and having a viscosity unsuitable for injection when dissolved in from about 0.5 ml to about 10 ml of water, wherein
the coated particles of the second population are about 0.5 mm to about 2 mm in diameter and are free from the opioid analgesic.
18. The controlled release oral solid dosage form of claim 17 , wherein the viscous gel has a viscosity of from 375 cP to 5000 cP.
19. The controlled release oral solid dosage form of claim 17 , wherein the viscous gel has a viscosity of from 2000 cP to 5000 cP.
20. The controlled release oral solid dosage form of claim 17 , wherein the viscous gel has a viscosity of from 120 cP to 5,000 cP.
21. A controlled release oral solid dosage form comprising a capsule containing:
(i) a first population of coated particles comprising an opioid analgesic coated with a controlled release material, and
(ii) a second population of coated particles comprising polyethylene oxide coated with an acrylic polymer,
the dosage form providing a therapeutic effect for about 12 hours to about 24 hours when orally administered to a human patient, and when dissolved in from about 0.5 ml to about 10 ml of water, forming a viscous gel,
wherein the coated particles of the second population are about 0.5 mm to about 2 mm in diameter and are free from the opioid analgesic.
22. The controlled release oral solid dosage form of claim 21 , wherein the coated particles of the first population are about 0.5 mm to about 2 mm in diameter.
23. The controlled release oral solid dosage form of claim 21 , wherein the viscous gel has a viscosity of from 10 cP to 60 cP.
24. The controlled release oral solid dosage form of claim 21 , wherein the viscous gel has a viscosity of from 120 cP to 5,000 cP.